.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
QuintilesIMS
Novartis
Moodys
Julphar
Teva
US Army
Cerilliant
Chubb
Harvard Business School

Generated: September 19, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020401

« Back to Dashboard
NDA 020401 describes TIAZAC, which is a drug marketed by Valeant Pharms North and is included in one NDA. It is available from eight suppliers. Additional details are available on the TIAZAC profile page.

The generic ingredient in TIAZAC is diltiazem hydrochloride. There are twenty-six drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the diltiazem hydrochloride profile page.

Summary for NDA: 020401

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 020401

Mechanism of ActionCalcium Channel Antagonists

Suppliers and Packaging for NDA: 020401

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TIAZAC
diltiazem hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL 020401 NDA Valeant Pharmaceuticals North America LLC 0187-2612 0187-2612-30 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (0187-2612-30)
TIAZAC
diltiazem hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL 020401 NDA Valeant Pharmaceuticals North America LLC 0187-2612 0187-2612-90 90 CAPSULE, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (0187-2612-90)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrength120MG
Approval Date:Sep 11, 1995TE:AB4RLD:Yes

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrength180MG
Approval Date:Sep 11, 1995TE:AB4RLD:Yes

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrength240MG
Approval Date:Sep 11, 1995TE:AB4RLD:Yes

Expired Orange Book Patents for NDA: 020401

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Pharms North
TIAZAC
diltiazem hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020401-001Sep 11, 1995► Subscribe► Subscribe
Valeant Pharms North
TIAZAC
diltiazem hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020401-005Sep 11, 1995► Subscribe► Subscribe
Valeant Pharms North
TIAZAC
diltiazem hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020401-004Sep 11, 1995► Subscribe► Subscribe
Valeant Pharms North
TIAZAC
diltiazem hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020401-003Sep 11, 1995► Subscribe► Subscribe
Valeant Pharms North
TIAZAC
diltiazem hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020401-002Sep 11, 1995► Subscribe► Subscribe
Valeant Pharms North
TIAZAC
diltiazem hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020401-006Oct 16, 1998► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Julphar
AstraZeneca
Boehringer Ingelheim
Daiichi Sankyo
Baxter
Medtronic
Covington
Fish and Richardson
Teva
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot